For best results when printing this announcement, please click on the linkbelow:
  http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130531:nPnLA23737
 Experienced Genomics Executive to Support Commercial Expansion in Europe andBeyondSAN DIEGO,  May 31, 2013  /PRNewswire/ --  BioNano Genomics, the developer ofthe Irys System for genome mapping, announced today the appointment of  FahimAmini, Ph.D. as vice president, Commercial Operations EMEA. Dr. Amini willfurther expand BioNano's commercial reach for the Irys System, making itpossible for researchers and clinicians in  Europe,  Middle East  and  Africa to access BioNano's recently launched Irys platform."As we prepare to expand access to the Irys System globally into  Europe  andbeyond, we are looking forward to meeting the needs of researchers andclinicians who require deeper insights into genome variations," said  ToddDickinson, Ph.D., vice president, Global Commercial Operations. "Fahim'saddition to the team at BioNano Genomics is a key component of our commercialroll-out in  Europe. Fahim has a proven track record in supporting labs in Europe, big and small, in the successful adoption of new platforms for genomeanalysis.""This is an exciting time in genomics research, especially with a commercialsystem that will propel the field of genomics, with all its tremendous advancesin the recent years, to the next level," said Dr. Amini.  "It is widely knownthat detecting structural variation and penetrating difficult repetitive regionswith today's short and medium-read technologies has been challenging.  Bypreserving the native genomic structure, the Irys System allows new insights tobe gained through direct visualization of genome structure, enabling thedetection of structural variation, significantly improving genome assemblies,phasing haplotypes, and many other applications yet to be developed. I am eagerto help researchers and clinicians throughout  Europe,  Middle East  and  Africa access BioNano's breakthrough genome mapping solution to drive newdiscoveries."Dr. Amini was most recently director of EMEA at Complete Genomics, where he wasresponsible for sustainable growth of CGI revenue and support structure. BeforeComplete Genomics, he held several commercial roles of increasing scope andresponsibility at Illumina, and prior to that, at Affymetrix. He received hisPh.D. in biological sciences and his BSc with honors in microbiology andmicrobial technology from the  University of Warwick, Coventry.   BioNano Genomics will be at the European Human Genetics Conference 2013presented by the European Society of Human Genetics (ESHG) taking place in Paris  from  June 8  to 11.  In addition,  Pui-Yan Kwok, M.D., Ph.D., HenryBachrach Distinguished Professor at the UCSF School of Medicine, will be givinga podium presentation on genome-wide structural variation analysis and de novosequence assembly at ESHG on  June 9th  at  1:15 pm  in the Grand Amphithatre.  About IrysIrys makes it possible to routinely and accurately detect genomic structuralvariation and to finish genome assemblies. The fully automated Irys benchtopinstrument uses the IrysChip to uncoil and confine long DNA molecules inproprietary Nanochannel Arrays where they are uniformly linearized in a highlyparallel display for high-resolution, single-molecule imaging. Irys does notemploy DNA fragmentation or amplification, which are typical withnext-generation sequencing. The result is sequence information over extremelylong "reads" ranging from hundreds of kilobases to a megabase, where thesample's valuable structural information is preserved. Irys makes it possiblefor researchers to directly observe structural variants including replications,deletions, translocations and inversions.About BioNano Genomics  Headquartered in  San Diego, BioNano Genomics is delivering an altogether betterway of gaining a fully informed understanding of genomes. The Company's platformprovides researchers and clinicians the most comprehensive, organized andactionable picture of a genome with unprecedented insights into how theindividual components of genomes are ordered, arranged, and interact with eachother. BioNano Genomics works with institutions in life science, translationalresearch, molecular diagnostics and personalized medicine. The Company issupported by private investors and grant funding from genomics programs atfederal agencies, including the NIH and NIST-ATP.  
  www.BioNanoGenomics.com
 Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other namesof actual companies, organizations, entities, products or services may be thetrademarks of their respective owners.SOURCE  BioNano GenomicsJessica Yingling Ph.D., Little Dog Communications, 858.344.8091,jessica@litldog.com